Zachary Glaser, MD
Urology · Twin Falls, IDNPI 1831622547
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Coloplast at 26.8% of the total. 2025 is the largest year on record at $8,308, more than ten times the $113 reported in 2019. Among urology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $83.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$4K
- Urogen Pharma, Inc.$2K
- Teleflex LLC$2K
- Boston Scientific$2K
- Bluewind Medical$887
- Olympus Winter & Ibe GmbH$875
- plus $4K from 22 others
What the payments were for
- Consulting fees$8756%
- Speaking & faculty fees$1,3008%
- Travel & lodging$4,82731%
- Food & beverage$8,33554%
- Education$650%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 37 | $4,120 |
| Urogen Pharma, Inc. | 11 | $2,240 |
| Teleflex LLC | 9 | $2,031 |
| Boston Scientific | 26 | $1,523 |
| Bluewind Medical | 8 | $887 |
| Olympus Winter & Ibe GmbH | 1 | $875 |
| Axonics, Inc. | 16 | $589 |
| Olympus America Inc. | 9 | $551 |
| Calyxo, Inc. | 3 | $429 |
| Procept Biorobotics Corporation | 4 | $255 |
| Laborie Medical Technologies Corp. | 3 | $227 |
| Dendreon Pharmaceuticals LLC | 2 | $212 |
| Astellas Pharma US Inc | 9 | $192 |
| Sumitomo Pharma America, Inc. | 8 | $175 |
| Endo Pharmaceuticals Inc. | 4 | $170 |
| Johnson & Johnson | 1 | $131 |
| Pfizer | 6 | $120 |
| Integra Lifesciences Corporation | 1 | $114 |
| AbbVie | 6 | $113 |
| Antares Pharma, Inc. | 3 | $99 |
| Valencia Technologies Corporation | 4 | $82 |
| Urovant Sciences Inc | 3 | $62 |
| Progenics Pharmaceuticals, Inc. | 2 | $47 |
| Medtronic | 2 | $46 |
| Merck | 2 | $42 |
| Hollister Incorporated | 2 | $34 |
| Civco Medical Instruments | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$3,158
- UroLift$1,688
- ZUSDURI$1,300
- Barrigel$1,082
- ENDOEYE FLEX DEFLECTABLE VIDEOSCOPE$875
- REVI$758
- GENERAL - THERAPIES$582
- Bulkamid$367
- Axonics$367
- CVAC Aspiration System$352
- iTIND System$318
- JELMYTO$255
- SpaceOAR VUE System - 10mL$153
- PROVENGE$149
- RYBREVANT$131
- CARVYKTI$131
- AQUABEAM SYSTEM$131
- BIOFIX$114
- BIODRESTORE$114
- MEDIHONEY$114
How this compares
$15,402 in reported general payments places this provider in the 95th percentile of 55 urology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 103 | $55,290 |
| OrgovyxRelugolix | 14 | $38,026 |
| GemtesaVibegron | 46 | $37,948 |
| Estradiol | 79 | $6,361 |
| Tamsulosin Hcl | 280 | $4,250 |
| Tolterodine Tartrate ErTolterodine Tartrate | 33 | $3,637 |
| Solifenacin Succinate | 48 | $3,032 |
| Testosterone Cypionate | 75 | $2,435 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 133 | $2,349 |
| Oxybutynin Chloride ErOxybutynin Chloride | 82 | $2,117 |
| Testosterone | 19 | $1,840 |
| Finasteride | 115 | $1,514 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 36 | $1,021 |
| NitrofurantoinNitrofurantoin Macrocrystal | 14 | $507 |
| Cefdinir | 23 | $329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $175 | $75,97460 claims |
| Astellas Pharma US IncMyrbetriq | $192 | $55,290103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 55 urology providers in Idaho.
Other urology in Twin Falls
- Michael SweeneyTwin Falls$5K
- Joel HancockTwin Falls$4K
- Jason GreenhalghTwin Falls$4K
- Andrew MazzoneTwin Falls$3K
- Edward MartinezTwin Falls$1K
- Jeremy WeissTwin Falls$1K
- Steven KurtzTwin Falls$623
- Nikolai SopkoTwin Falls$488
- Cory BatesTwin Falls$431
- Sean StroupBoise$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.